Solventum (NYSE:SOLV) Updates FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 6.600-6.600 for the period, compared to the consensus earnings per share estimate of 6.470. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. BTIG Research restated a “buy” rating and issued a $100.00 price target on shares of Solventum in a research note on Friday, February 27th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Rothschild & Co Redburn assumed coverage on Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. Mizuho set a $100.00 price target on Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $89.45.

Solventum Stock Performance

Shares of SOLV stock traded up $1.65 on Tuesday, reaching $69.09. The stock had a trading volume of 1,942,446 shares, compared to its average volume of 1,209,391. The stock has a market cap of $11.98 billion, a P/E ratio of 7.79, a price-to-earnings-growth ratio of 1.09 and a beta of 0.59. Solventum has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. The company has a 50 day simple moving average of $67.99 and a 200 day simple moving average of $74.53.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts expect that Solventum will post 6.5 EPS for the current year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.24% of the company’s stock.

Hedge Funds Weigh In On Solventum

Institutional investors have recently bought and sold shares of the stock. CrossGen Wealth LLC bought a new position in Solventum in the 4th quarter worth $25,000. Measured Wealth Private Client Group LLC bought a new position in Solventum in the 3rd quarter worth $25,000. CYBER HORNET ETFs LLC bought a new position in Solventum in the 2nd quarter worth $28,000. MUFG Securities EMEA plc bought a new position in Solventum in the 2nd quarter worth $31,000. Finally, State of Wyoming bought a new position in Solventum in the 2nd quarter worth $33,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.